Junevity, a biotechnology company on a mission to extend lifespan and healthspan with cell reprogramming, raised $10 million in new funding, bringing its Seed financing to a total of $20 million. The new funding, led by Goldcrest Capital and Godfrey Capital, enables Junevity to advance the company's lead siRNA (silencing RNA) program for type 2 diabetes and obesity, JUN_01, through IND-enabling and initial clinical studies. The founders of Junevity were the first to demonstrate that repressing a single transcription factor can reprogram cell state to health in human cell models.